Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Ann N Y Acad Sci. 2011 Jan;1215:150–160. doi: 10.1111/j.1749-6632.2010.05852.x

Table 2. Chemosensitization of Tumors by Resveratrol.

Chemotherapeutic agent Tumor type Mechanism
Cytotoxic drugs Tumor cells Cell cycle arrest, Surviving↓ 44
Cisplatin, Gefitinib, Paclitaxel NSCLC Survivin ↓ 45
Paclitaxel NHL and MM Bcl-xL ↓ 46
5-FU Colon cancer cells Centrosome amplification56 Caspase-6 ↑a 47
Velcade MM and T cell leukemia Fas/CD95 recruitment 48
Doxorubcin Melanoma Cyclin D1 ↓ and p53 ↑ 49
Vincristine, adriamycin, Oral carcinoma p-glycoprotein ↓, Bcl-2 ↓51
Paclitaxel KBv200 cells
Doxorubicin AML cells MRP1 ↓52
Paclitaxel Lung cancer cells p21waf1 ↑ 53
Velcade, thalidomide MM NF-κB ↓ and STAT-3 ↓ 42
Gemcitabine Pancreatic cancer NF-κB ↓ 57
Anticancer agents HL60/VCR58
Doxorubicin, cisplatin Ovarian and uterine cancer cells59
Gemcitabine Pancreatic cancer cells60

AML, acute myeloid leukemia; Bcl-2, B cell lymphoma-2; Bcl-xL, B cell lymphoma extra large; 5-FU, 5-fluorouracil; MM, multiple myeloma; MRP, multi-drug resistance associated protein; NF-κB, nuclear factor kappa B; NHL, Non-Hodgkin Lymphoma; NSCLC, non small cell lung cancer; STAT-3, signal transducers and activators of transcription protein-3; ↑, up-regulation; ↓, down-regulation; ↑a, activation.